* The Accu-Chek® SmartGuide CGM solution provides 14 days of accurate(1) real-

    time glucose values for adults living with type 1 and type 2 diabetes on
    flexible insulin therapy.
  * The built-in AI-trained algorithms will empower users to proactively
    intervene when their glucose levels require attention and before a
    complication can even occur.
  * The solution is set to launch in selected European markets in the coming
    months.

Basel, 09 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it
has received the CE Mark for its Accu-Chek SmartGuide® continuous glucose
monitoring (CGM) solution. This significant milestone paves the way for the
solution to be made available to people living with type 1 and type 2 diabetes
over the age of 18 on flexible insulin therapy.
"Maintaining optimal blood glucose levels and preventing adverse glycaemic
episodes remains a complex task for people living with diabetes, often
necessitating up to 180 therapy decisions a day(2)," said Matt Sause, CEO of
Roche Diagnostics. "Our novel CGM solution with its predictive algorithms will
help address significant unmet needs associated with diabetes management,
empowering users to take control of their condition and live better and
healthier lives."
Despite CGM technology's demonstrated positive impact on glycaemic control,(3) a
significant proportion of people living with diabetes still do not meet
glycaemic targets - even when using a CGM system.(4) Moreover, they typically
encounter an average of two hypoglycaemic episodes a week, with 1-2 of these
being severe enough to require medical intervention each year.(5) Notably,
nighttime hypoglycaemia is associated with reduced quality of life, increased
anxiety, and fear. The persistent fear of hypoglycaemia, hypoglycaemia
unawareness, sleep disruption, and diabetes-related distress among CGM users
frequently correlates with elevated glucose levels.(6)
The Accu-Chek SmartGuide CGM solution aims to address those critical unmet
needs. Every five minutes, the Accu-Chek SmartGuide CGM sensor sends glucose
values measured in real time to the Accu-Chek SmartGuide app. The Accu-Chek
SmartGuide Predict app then utilises those glucose values and other available
information to detect glucose patterns and predict future glucose levels. Its
integrated AI-enabled predictive algorithms indicate hypoglycaemia risk within
the next 30 minutes, continuously forecast how glucose levels will develop
within the next two hours, and estimate the risk of nocturnal hypoglycaemia. As
such, Roche's new CGM solution is designed to alleviate people living with
diabetes' and caregivers' concerns about nighttime hypoglycaemia and lower its
risk. It aims to support informed therapy self-management decisions, enabling
proactive intervention before glucose levels require immediate attention.
Clinical evaluations have demonstrated the new CGM solution's high system
accuracy, with an overall mean absolute relative difference (MARD) of 9.2% and
99.8% of measured glucose values falling within zones A and B on the Parkes
Error Grid.(7) The evaluation of the predictive capabilities showed that all
advanced predictive features exceeded high performance requirements as e.g.
accuracy, sensitivity, specificity, and events detected.(1)
About the Accu-Chek SmartGuide CGM solution
Accu-Chek SmartGuide is a continuous glucose monitoring (CGM) solution developed
by Roche providing accurate real-time glucose readings and predictions for
different timeframes. The solution includes 3 elements: the Accu-Chek SmartGuide
CGM sensor, the Accu-Chek SmartGuide App and the Accu-Chek SmartGuide Predict
App. With an all-in-one applicator and 14-day wear time, Accu-Chek SmartGuide is
designed for people living with diabetes type 1 and type 2 on flexible insulin
therapy, 18 years of age and older. It aims at empowering people living with
diabetes to be prepared for the future course of glucose levels and take
preventive action by making the appropriate therapy adjustments in good time.
The Accu-Chek SmartGuide solution seamlessly integrates with the Accu-Chek® Care
platform, offering healthcare professionals (HCP) access to comprehensive and
accurate therapy-relevant data provided by the CGM solution. This integration
allows HCPs to analyse together with their patients how lifestyle and therapy
impact their glucose levels and make more informed decisions. Such personalised
care can lead to improved outcomes.that
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial
manufacturers of branded medicines, Roche has grown into the world's largest
biotechnology company and the global leader in in-vitro diagnostics. The company
pursues scientific excellence to discover and develop medicines and diagnostics
for improving and saving the lives of people around the world. We are a pioneer
in personalised healthcare and want to further transform how healthcare is
delivered to have an even greater impact. To provide the best care for each
person we partner with many stakeholders and combine our strengths in
Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavour to pursue a long-term perspective in all we do,
Roche has been named one of the most sustainable companies in the
pharmaceuticals industry by the Dow Jones Sustainability Indices for the
fifteenth consecutive year. This distinction also reflects our efforts to
improve access to healthcare together with local partners in every country we
work.
Genentech, in the United States, is a wholly owned member of the Roche Group.
Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com (http://www.roche.com).
All trademarks used or mentioned in this release are protected by law.
References
(1) Mader, J. K. et al., 1924-LB: Clinical Performance of a Novel CGM System.
Diabetes 14 June 2024; 73 (Supplement_1): https://doi.org/10.2337/db24-1924-LB /
Roche Data on file
(2) ) Erin Digitale Scopeblog Stanford. (2017-11-29),
https://scopeblog.stanford.edu/2014/05/08/new-research-keeps-diabetics-safer-
during-sleep/
(3) Carlson AL, et al., Diabetes Technol Ther., 2017 May;19(S2):S4-S11. doi:
10.1089/dia.2017.0024
(4) DeSalvo DJ, et al., Journal of Diabetes Science and Technology.
2023;17(2):322-328
(5) Leese, G.P. et al., Diabetes Care 2003, Apr 26 (4): 1176-80; Elliot, L. et
al., Diabetes Ther 7, 45-60 (2016); Graveling, A. J. et al., Prim Care Diabetes,
2009; 3: 131-139
(6) DCCT Research Group. The American journal of medicine. 1991 Apr
1;90(4):450-9
(7) Parkes Error Grid - a tool to evaluate the accuracy of glucose monitoring
sytems (BGM and CGM)
Calibration required for insulin dosing as requested by the Accu-Chek SmartGuide
app
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
(mailto:media.relations@roche.com)

  Hans Trees, PhD           Sileia Urech
  Phone: +41 79 407 72 58   Phone: +41 79 935 81 48
  Nathalie Altermatt        Simon Goldsborough
  Phone: +41 79 771 05 25   Phone: +44 797 32 72 915
  Karsten Kleine            Nina Mählitz
  Phone: +41 79 461 86 83   Phone: +41 79 327 54 74
  Kirti Pandey              Yvette Petillon
  Phone: +49 172 6367262    Phone: +41 79 961 92 50
  Dr. Rebekka Schnell       Lorena Corfas
  Phone: +41 79 205 27 03   Phone: +34 620 29 25 51

Roche Investor Relations

 Dr. Bruno Eschli                        Dr. Sabine Borngräber
 Phone: +41 61 68-75284                  Phone: +41 61 68-88027
 e-mail: bruno.eschli@roche.com          e-mail: sabine.borngraeber@roche.com
 (mailto:bruno.eschli@roche.com)         (mailto:sabine.borngraeber@roche.com)
                                          (mailto:sabine.borngraeber@roche.com)

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
(mailto:birgit.masjost@roche.com)
Investor Relations North America

  Loren Kalm
  Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com (mailto:kalm.loren@gene.com)Â